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Abstract
Purpose—Pharmacogenetic (PGx) testing can inform drug dosing and selection by aiding in
estimating a patient’s genetic risk of adverse response and/or failure to respond. Some PGx tests
may generate ancillary clinical information unrelated to the drug treatment question for which
testing is done – an informational “side effect.” We aimed to assess public interest and concerns
about PGx tests and ancillary information.
Methods—We conducted a random-digit-dial phone survey of a sample of the U.S. public.
Results—We achieved an overall response rate of 42% (n=1,139). When the potential for
ancillary information was presented, 85% (±2.82%) of respondents expressed interest in PGx
testing, compared to 82% (±3.02%) prior to discussion of ancillary information. Most respondents
(89%±2.27%) indicated that physicians should inform patients that a PGx test may reveal ancillary
risk information before testing is ordered. Respondents’ interest in actually learning of the
ancillary risk finding significantly differed based on disease severity, availability of an
intervention, and test validity, even after adjusting for age, gender, education and race.
Conclusion—Under the limited information conditions presented in the survey, the potential of
ancillary information does not negatively impact public interest in PGx testing. Interest in learning
ancillary information is well-aligned with the public’s desire to be informed about potential
benefits and risks prior to testing, promoting patient autonomy.
INTRODUCTION
Genetic variation accounts for 20 to 95% of the variation in individual responses to
medications.1 Based on the enhanced understanding of the role of genetic variation in drug
response, many drug labels have been revised to include information about the impact of
genetic variation on drug response and pharmacogenetic (PGx) testing.2 Specifically, PGx
testing can inform therapeutic decision-making through awareness of a patient’s likelihood
of an adverse event or responding poorly or not at all to a prescribed medication.
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PGx tests have been considered to have fewer ethical and social implications than disease-
based genetic testing given the immediate application of the test result to treatment decisions
and reduced potential for stigmatization and discrimination.3, 4 One concern, however, is the
potential for PGx tests to generate ancillary clinical information unrelated to the drug
treatment question for which testing is performed and the associated harms and challenges
related to management of the information – an informational “side effect.” Ancillary
information may include insights about other disease predispositions, prognosis, and drug
responses. For example, the APOE4 allele has been associated with decreased warfarin dose
requirements5, 6 and statin response,7, 8 and hence can help guide warfarin dosing or statin
selection; this PGx test can also provide information about risk of Alzheimer disease9 or
age-related macular degeneration,10 diseases with few preventive interventions or available
treatments.
The number of PGx tests that reveal ancillary information is uncertain. One study reported
that more than half of validated PGx variants analyzed had an association with disease risk;
16% of the variants were linked with two different diseases, some of which are potentially
stigmatizing conditions.11 Incidental findings occurring in other types of medical
applications such as imaging present a somewhat comparable issue since highly sensitive
imaging techniques generate a high prevalence of incidental findings in some tissues (e.g.,
kidney and adrenal gland), creating dilemmas for both patients and physicians.12–15
Several factors may contribute to the potential harm or benefit of learning of genetic
susceptibility, such as the nature of disease, the test’s predictive value, and availability of
interventions or treatment to reduce disease risk.16 While the obligation to disclose ancillary
information or inform a patient of its existence will be influenced by legal standards and
case law, clinical practice norms will likely be affected by patient expectations and
preferences. A proposed framework to address some issues related to the use of PGx tests
includes consideration of ancillary information.17 Currently, there are no reported studies
about public perspectives regarding ancillary information and its effects on test uptake. We
sought to fill this gap by conducting a national survey of the general public about PGx
testing and ancillary information. We hypothesized that the public would be interested in
being informed of ancillary information prior to deciding to undergo PGx testing given the
emphasis on patient autonomy. However, interest in learning of the risk information would
be influenced by the level of risk, the availability of a treatment/intervention for the disease,
disease severity, and the accuracy of the predicted risk. We anticipate the data from this
study will be helpful in informing physician practices regarding disclosure of ancillary
information, potentially informing development of clinical guidelines regarding the
management of such information.
MATERIALS AND METHODS
Survey Development
We developed a survey to explore public attitudes regarding PGx testing and the role
ancillary information might play in decisions to undergo such tests. The survey questions
were developed based on data collected from focus groups, a literature review, and a legal
analysis of managing ancillary findings. Four focus groups were convened to explore public
perceptions and attitudes about PGx testing, and specifically about the impact of ancillary
information. We defined ancillary information for the focus group participants as “extra
information such as your risk of developing a disease,” and that it was most likely “not
related to your current health.” We then discussed a fictional case about an asthma patient
who has PGx testing to predict her risk of a serious adverse effect associated with a new
medication that her doctor wishes to prescribe; the PGx test could also reveal her risk of
colon cancer. Many participants believed that their physician should disclose the potential of
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ancillary information prior to testing, however, their desire to actually learn of that
information varied based on the whether an intervention was available and potential
psychological burden (data unpublished). Although not a nationally representative sample,
the focus groups served to increase our understanding of public attitudes toward PGx testing
and ancillary information and inform development of the survey instrument.
Survey Pilot
As described elsewhere,18 piloting and administration of the survey was led by the Survey
Research Unit at the University of North Carolina, Chapel Hill. A pretest was conducted in
August 2009 with 52 North Carolina residents to evaluate the quality of the computer-
assisted telephone interviewing (CATI) programming and appropriateness of the content for
telephone administration. The final survey contained 52 questions in five major categories:
1) demographics; 2) personal/family experience with prescription medications; 3)
knowledge of genetic testing; 4) interest in PGx testing given certain risks and uses of
testing; and 5) attitudes towards management of ancillary information revealed by PGx
testing. We report here data regarding attitudes towards management of ancillary
information; see ref. 18 for other survey findings.
Sampling methods
In summary, a stratified random digit dial sample of 20,848 telephone numbers in the U.S.
was selected for this survey. Eligibility was based on reaching a household with an English-
speaking resident 18 years of age or older. Households were classified as non-responsive
(eligible but no interview; n=1,010), ineligible (non-residential numbers, non-English
speaking households, or head of household under 18 years of age; n=14,335), or unknown
(eligibility never verified; n=4,364). If more than one eligible adult resided in the household,
one was randomly selected for participation via a computer-generated algorithm. We
calculated a response rate of 42% (n=1139) based on the standards and definitions set by the
American Association of Public Opinion Research.19
Data Collection
The survey was conducted from September 17 to November 20, 2009. A CATI interview
software package (Blaise 4.6, 2003) was used to assist interviewers in the administration of
the survey and to manage all call attempts. At least 12 call attempts were made per each
telephone number at various times of the day and week. For quality control, all interviewers
were monitored periodically and written feedback provided. This study was approved by the
Institutional Review Boards at Duke University Medical Center and the University of North
Carolina, Chapel Hill.
Data Analysis
Respondents tended to be older, White, and female to a greater extent than would be
expected by chance alone. To correct for such sample imbalances and reduce the potential
effects of bias, the survey data were adjusted by age (18–34, 35–54, 55 & older), White and
non-White, and gender based on normative data from the 2008 American Community
Survey.20 Questions using a 4-point Likert scale were dichotomized into “likely and
“unlikely.” For logistic regression analyses, model building was based on hypothetically-
related covariates with adjustment for demographic characteristics; final variable selection
was conducted using the backward selection approach. Odds ratios and corresponding 95%
confidence intervals were computed; significance level of 0.05 was used for all statistical
tests. To adjust for control variables, Cochran-Mantel-Haenszel (CMH) test was applied
when comparing two groups on a binary response. All analyses were conducted in SAS
(Version 9.1.3 using Proc Frequency, Proc Logistic & Proc Regression).
Haga et al. Page 3















After adjustment, respondents were 51% female, 78% White, and between the ages of 34–55
years (38%).18 Forty-two percent of respondents had a college degree or higher. In addition,
the majority of respondents had some type of health insurance (86%), predominantly
provided through their employer (75%). Forty-seven percent had experienced a side effect
from a prescription drug; of those, 80% had stopped taking the drug of their own accord or
by physician’s orders. Seventy-nine percent of respondents characterized their health status
as excellent or good, comparable to national reports of self-rated health status.21, 22 Eighty
percent of respondents had heard of genetic testing; 54% of those that had heard of genetic
testing indicated they understood the uses of genetic testing ‘very well’ or ‘somewhat well.’
Disclosure of Potential Ancillary Information
We described to respondents how some PGx tests may reveal “additional” information, not
related to their current condition using the following situational context: “Before having
some minor surgery, your doctor wishes to order a genetic test to determine how much pain
medication to give you. Because genes perform many jobs, the genetic test results may show
other information in addition to drug response information your doctor needs. For example,
the genetic drug response test may also show your risk for developing a certain disease
during your lifetime.”
Overall, 89% (±2.27%) of respondents indicated that physicians should inform patients that
a PGx test may reveal ancillary risk information unrelated to their current condition before a
decision about PGx testing is made. Respondents who believed a doctor should inform
patients about ancillary information prior to testing were more likely to have testing to
predict drug response after hearing about the potential uses of PGx testing (OR=3.59,
p<0.0001, 95% CI [2.12, 6.04]). No statistically significant relationships were detected
between disclosure of potential for ancillary information prior to testing and age, education,
race, health insurance status, health status, or being affected (self or family member) with a
chronic condition.
Interest in Learning Ancillary Risk Information
We then asked respondents about their interest in learning of six potential types of ancillary
risk information: 1) risk for a disease considered minor but treatable such as gum disease; 2)
risk for a disease considered serious but treatable such as heart disease; 3) risk for a disease
considered serious but untreatable such as dementia or Alzheimer’s; 4) risk for a disease
that would not develop for at least 10 years; 5); a disease with a moderately low risk; and 6)
risk that was unclear and uncertain. “Interest” was defined as “extremely interested” or
“somewhat interested” in PGx testing. Respondents’ interest in learning of the different
types of ancillary information ranged from a low of 69% (ancillary information of uncertain
risk, ±3.40%) to a high of 96% (±1.23%) for risk of serious but treatable disease (Figure 1).
Interest level was found to be significantly different between the ancillary risk information
scenarios, even after adjusting for age, gender, education and race (CMH statistic of general
association: 144.70, p<0.0001).
Factors Associated with Interest in Learning Ancillary Risk Information
Women were less interested in learning of the ancillary risk information for four of the six
scenarios presented: minor but treatable disease, serious but treatable disease, moderately
low disease risk, and uncertain or unknown disease risk (Table 1). Respondents with a
college degree were less likely to be interested in learning of ancillary risk information for
serious and untreatable disease and diseases with uncertain risk. A history of side effects
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increased interest in only one scenario – for a minor but treatable disease. As compared to
non-White respondents, White respondents were less likely to indicate interest in learning of
a moderately low disease risk or uncertain disease risk.
Impact of Potential Ancillary Information on Overall Interest in PGx testing
Prior to introduction of the potential for ancillary information and the different types of
ancillary information, 82% (±3.02%) of respondents expressed strong interest in PGx testing
after learning of some of the general risks and uses of testing.18 After learning of the
potential for and the different types of ancillary information, 85% (±2.82%) of respondents
indicated that they would be extremely or somewhat likely to have PGx testing. After
adjusting for age, level of education, race and sex, interest in PGx testing increased
significantly when compared to interest assessed after learning of potential risks only (CMH
statistic of general association: 162.62, p<0.0001) and risks and potential uses (CMH
statistic of general association: 358.95, p<0.0001).
DISCUSSION
The management of ancillary information from PGx testing raises many issues for both
physicians and patients. From the patient perspective, questions arise as to whether patients
should be informed about ancillary information prior to testing, their desire to learn of the
risk information, and what factors influence these decisions. In addition, the potential of
ancillary findings unrelated to the drug treatment question for which testing is performed
may impact patient and physician interest in these tests. Physician enthusiasm for PGx
testing for smoking cessation treatments has been reported to be lessened by the potential for
ancillary risk information, especially for stigmatizing conditions.23–25 We found this was
not the case for the general public; interest in PGx testing remained high after respondents
were informed about the potential for ancillary information. The high interest suggests that
the public is more interested in PGx testing than their physicians might anticipate and do not
consider ancillary information to be a major drawback of testing, and may, in some cases,
consider it an added benefit.
Most respondents felt physicians should inform patients about potential ancillary
information prior to PGx testing. The strong interest in being informed prior to testing is in
line with the increasingly active role of patients in the decision-making process for medical
care.26 However, disclosure of ancillary information leaves uncertainties with respect to
informed consent standards of liability. For example, what types of ancillary information
should the patient be informed about prior to their decision to undergo PGx testing – any
type of ancillary information or only that for diseases with available interventions?
If ancillary risk information for untreatable or potentially stigmatizing conditions could be
revealed by a PGx test, such as Alzheimer’s disease5–9 or mental illness,11 the test may be
considered “high” risk requiring a detailed consent process.4, 27 It is not only the existence
of ancillary information, but the characteristics of that information that would dictate the
appropriate level of consent.28 Furthermore, in addition to discussing the potential of the
ancillary information prior to making a decision to undergo PGx testing, it may be prudent
to also discuss the potential benefits and harms of learning of the information. For example,
potential clinical follow-up of ancillary risks may lead to costly and/or potentially risky
interventions.29–31 In research settings, some scholars have recommended that the potential
for ancillary information should be disclosed to research subjects during the informed
consent.32 While informed consent is standard practice for most clinical research studies, it
is not routinely obtained for PGx testing in general,33 particularly for tests considered
standard of care,34, 35 and therefore, would result in a major change in practice.
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Although most respondents wished to know about ancillary information prior to testing,
interest in learning of the information varied between respondents. Some of this variability
may be attributed to differences in interpretation of the descriptors used in the survey
(serious versus moderate risk), or treatable. In addition, our presentation of risk (i.e., low)
could have influenced respondents’ interest given that different ways of presenting risk
(numerical risks such as relative risk versus descriptive risks) can impact response and
understanding.36 As it was not feasible to ask about their interest in ancillary information
based on a combination of factors that would be disclosed in an actual clinical situation
(e.g., level of uncertainty and availability of treatment and disease characteristics), we might
expect even greater differences in attitudinal responses. Such limited information scenarios
may account for differences between higher expressed levels of interest and lower rates of
actual test uptake37, 38 as well as disparities in physician and public attitudes regarding
ancillary information.
Not surprisingly, respondents were most interested in learning of risks for serious but
treatable diseases and least interested in learning of uncertain risks. College graduates were
the only group who were less likely to want to learn of their risk for serious but untreatable
diseases. Two possible reasons that may account for this finding are fear of discrimination or
desire to avoid potential anxiety and stress. A recent study of personalized genomic risk
assessments reported that 82% would want to know of risks for serious diseases that could
not be prevented.39
Women were less likely to want to learn of ancillary risks for several scenarios. These
findings comport with previous work suggesting that women have greater dread of risks,40
and specifically, greater concerns about personalized genomic risk assessments.39 Positive
carrier test results for women have also been shown to result in greater anxiety than for
positive male carriers,41, 42 perhaps due to the greater perceived value and benefits of testing
for women given the implications for reproductive decision-making.43 The trend toward not
wanting to learn of certain types of ancillary risk appears in contrast with the understanding
that women are typically active health information seekers.44 Women pre-dominantly make
most of the health care decisions for themselves and family members,45 based on a
combination of personal values, beliefs, and past experiences.46 Perceived lack of control
has been associated with failure to partake in some beneficial health behaviors,47 but this
reasoning does not explain our finding that women were less interested in genomic-based
risk for treatable diseases (mild or serious) compared to untreatable. Few studies have
examined interest or experience in genetic risk information for serious, non-treatable
disease. A study involving APOE genotyping for Alzheimer’s risk in individuals with a
family history of Alzheimer reported that a high proportion of interested participants were
female and well-educated,48 suggesting that treatability may only be one criterion
considered when deciding to learn of such risk information.
As PGx testing progresses in clinical practice, it is essential to consider the consequences of
informational side effects for the patient and their care. The issue of ancillary or incidental
findings, particularly in genome research,49 has garnered recent attention due to the volumes
of data that can be generated in a single study from sequencing or other technology
platforms and concerns about how the data should be appropriately managed.50–52 The
strong interest in learning about ancillary information is well-aligned with the public’s
desire to be informed about benefits and risks of testing, thus empowering them with the
autonomy to make an informed decision about testing. Awareness of the potential for
ancillary information may be considered material to patients’ decisions about PGx testing.
However, despite their interest, from an ethical and legal perspective, it is still uncertain
whether all types of ancillary information should be disclosed. Thus, further study is
warranted to examine the types of ancillary information that should be disclosed to patients
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during discussion of PGx testing, whether patients choose to learn of the information and the
benefits and harms associated with learning it, and the delivery of ancillary information.
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Survey respondents’ interest in learning of various types of ancillary risk information
revealed by PGx testing. Interest level was significantly different between the ancillary
information scenarios, even after adjusting for age, gender, education and race (based on
Cochran-Mental-Haenszel test, p<0.0001).
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